GlassScriptPhysician profile
Sean William Welsh
NPI 1619232493
$2,164.49
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,608 · 2020: $373 · 2021: $35.67 · 2022: $63.31 · 2023: $83.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $83.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $83.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $301.37 | 2019-2023 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $200.21 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $187.18 | 2019-2020 | |
| Astellas Pharma US INC | $149.47 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $145.03 | 2019-2020 | |
| Allergan, INC. | $134.14 | 2019-2020 | |
| Glaxosmithkline, LLC. | $123.67 | 2019-2020 | |
| Dexcom, INC. | $123.13 | 2022-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $94.34 | 2019-2020 | |
| Lilly USA, LLC | $93.91 | 2019 | |
| Mylan Specialty L.P. | $68.81 | 2019 | |
| Janssen Pharmaceuticals, INC | $56.79 | 2019 | |
| Radius Health, INC. | $53.83 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.06 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.72 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47.17 | 2019 | |
| Pfizer INC. | $45.98 | 2019-2020 | |
| Celgene Corporation | $41.56 | 2019 | |
| Vertiflex, INC. | $31.11 | 2019 | |
| Avanir Pharmaceuticals, INC. | $22.50 | 2019 | |
| Abbott Laboratories | $19.34 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.75 | 2020 | |
| Scilex Pharmaceuticals INC. | $18.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.63 | 2020 | |
| Supernus Pharmaceuticals, INC. | $16.47 | 2020 | |
| Circassia INC. | $16.43 | 2019 | |
| Abbvie INC. | $16.33 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.01 | 2019 | |
| Amarin Pharma, INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Welsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.